Global Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Insights, Forecast to 2030

Publication ID:

PB511247629

Publication Date:

November 13, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

麻豆原创 Analysis and Insights: Global Non- Alcoholic Steatohepatitis Treatment 麻豆原创
The global Non- Alcoholic Steatohepatitis Treatment market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Non- Alcoholic Steatohepatitis Treatment market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Non- Alcoholic Steatohepatitis Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Non- Alcoholic Steatohepatitis Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Non- Alcoholic Steatohepatitis Treatment revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Non- Alcoholic Steatohepatitis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Non- Alcoholic Steatohepatitis Treatment revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Gilead Sciences
Bristol Myers Squibb
Novo Nordisk
NGM Biopharmaceuticals
Galectin Therapeutics
Inventiva Pharma
Intercept Pharmaceuticals
AbbVie
Madrigal Pharmaceuticals
Segment by Type
Cenicriviroc
Aramchol
Resmetirom
Semaglutide
Lanifibranor
Obeticholic Acid (OCA)
Segment by Application
Retail & Specialty Pharmacies
Hospital Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Non- Alcoholic Steatohepatitis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non- Alcoholic Steatohepatitis Treatment companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non- Alcoholic Steatohepatitis Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Cenicriviroc
1.2.3 Aramchol
1.2.4 Resmetirom
1.2.5 Semaglutide
1.2.6 Lanifibranor
1.2.7 Obeticholic Acid (OCA)
1.3 麻豆原创 by Application
1.3.1 Global Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Retail & Specialty Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Perspective (2019-2030)
2.2 Global Non- Alcoholic Steatohepatitis Treatment Growth Trends by Region
2.2.1 Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non- Alcoholic Steatohepatitis Treatment Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Non- Alcoholic Steatohepatitis Treatment Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Dynamics
2.3.1 Non- Alcoholic Steatohepatitis Treatment Industry Trends
2.3.2 Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Drivers
2.3.3 Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Challenges
2.3.4 Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Non- Alcoholic Steatohepatitis Treatment by Players
3.1.1 Global Non- Alcoholic Steatohepatitis Treatment Revenue by Players (2019-2024)
3.1.2 Global Non- Alcoholic Steatohepatitis Treatment Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Non- Alcoholic Steatohepatitis Treatment, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Concentration Ratio
3.4.1 Global Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non- Alcoholic Steatohepatitis Treatment Revenue in 2023
3.5 Global Key Players of Non- Alcoholic Steatohepatitis Treatment Head office and Area Served
3.6 Global Key Players of Non- Alcoholic Steatohepatitis Treatment, Product and Application
3.7 Global Key Players of Non- Alcoholic Steatohepatitis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non- Alcoholic Steatohepatitis Treatment Breakdown Data by Type
4.1 Global Non- Alcoholic Steatohepatitis Treatment Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Non- Alcoholic Steatohepatitis Treatment Forecasted 麻豆原创 Size by Type (2025-2030)
5 Non- Alcoholic Steatohepatitis Treatment Breakdown Data by Application
5.1 Global Non- Alcoholic Steatohepatitis Treatment Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Non- Alcoholic Steatohepatitis Treatment Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size (2019-2030)
6.2 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type
6.2.1 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Type (2019-2030)
6.3 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application
6.3.1 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Application (2019-2030)
6.4 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country
6.4.1 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size (2019-2030)
7.2 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type
7.2.1 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Type (2019-2030)
7.3 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application
7.3.1 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Application (2019-2030)
7.4 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country
7.4.1 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size (2019-2030)
8.2 China Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type
8.2.1 China Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2019-2024)
8.2.2 China Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2025-2030)
8.2.3 China Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Type (2019-2030)
8.3 China Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application
8.3.1 China Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2019-2024)
8.3.2 China Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2025-2030)
8.3.3 China Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size (2019-2030)
9.2 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type
9.2.1 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Type (2019-2030)
9.3 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application
9.3.1 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Application (2019-2030)
9.4 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Region
9.4.1 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Non- Alcoholic Steatohepatitis Treatment 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Details
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Non- Alcoholic Steatohepatitis Treatment Introduction
11.1.4 Gilead Sciences Revenue in Non- Alcoholic Steatohepatitis Treatment Business (2019-2024)
11.1.5 Gilead Sciences Recent Developments
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Non- Alcoholic Steatohepatitis Treatment Introduction
11.2.4 Bristol Myers Squibb Revenue in Non- Alcoholic Steatohepatitis Treatment Business (2019-2024)
11.2.5 Bristol Myers Squibb Recent Developments
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Non- Alcoholic Steatohepatitis Treatment Introduction
11.3.4 Novo Nordisk Revenue in Non- Alcoholic Steatohepatitis Treatment Business (2019-2024)
11.3.5 Novo Nordisk Recent Developments
11.4 NGM Biopharmaceuticals
11.4.1 NGM Biopharmaceuticals Company Details
11.4.2 NGM Biopharmaceuticals Business Overview
11.4.3 NGM Biopharmaceuticals Non- Alcoholic Steatohepatitis Treatment Introduction
11.4.4 NGM Biopharmaceuticals Revenue in Non- Alcoholic Steatohepatitis Treatment Business (2019-2024)
11.4.5 NGM Biopharmaceuticals Recent Developments
11.5 Galectin Therapeutics
11.5.1 Galectin Therapeutics Company Details
11.5.2 Galectin Therapeutics Business Overview
11.5.3 Galectin Therapeutics Non- Alcoholic Steatohepatitis Treatment Introduction
11.5.4 Galectin Therapeutics Revenue in Non- Alcoholic Steatohepatitis Treatment Business (2019-2024)
11.5.5 Galectin Therapeutics Recent Developments
11.6 Inventiva Pharma
11.6.1 Inventiva Pharma Company Details
11.6.2 Inventiva Pharma Business Overview
11.6.3 Inventiva Pharma Non- Alcoholic Steatohepatitis Treatment Introduction
11.6.4 Inventiva Pharma Revenue in Non- Alcoholic Steatohepatitis Treatment Business (2019-2024)
11.6.5 Inventiva Pharma Recent Developments
11.7 Intercept Pharmaceuticals
11.7.1 Intercept Pharmaceuticals Company Details
11.7.2 Intercept Pharmaceuticals Business Overview
11.7.3 Intercept Pharmaceuticals Non- Alcoholic Steatohepatitis Treatment Introduction
11.7.4 Intercept Pharmaceuticals Revenue in Non- Alcoholic Steatohepatitis Treatment Business (2019-2024)
11.7.5 Intercept Pharmaceuticals Recent Developments
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Non- Alcoholic Steatohepatitis Treatment Introduction
11.8.4 AbbVie Revenue in Non- Alcoholic Steatohepatitis Treatment Business (2019-2024)
11.8.5 AbbVie Recent Developments
11.9 Madrigal Pharmaceuticals
11.9.1 Madrigal Pharmaceuticals Company Details
11.9.2 Madrigal Pharmaceuticals Business Overview
11.9.3 Madrigal Pharmaceuticals Non- Alcoholic Steatohepatitis Treatment Introduction
11.9.4 Madrigal Pharmaceuticals Revenue in Non- Alcoholic Steatohepatitis Treatment Business (2019-2024)
11.9.5 Madrigal Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Gilead Sciences
Bristol Myers Squibb
Novo Nordisk
NGM Biopharmaceuticals
Galectin Therapeutics
Inventiva Pharma
Intercept Pharmaceuticals
AbbVie
Madrigal Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.